tradingkey.logo
搜尋

ImmuCell Corp

ICCC
添加自選
11.210USD
+0.150+1.36%
收盤 07-31 16:00美東報價延遲15分鐘
101.40M總市值
虧損本益比TTM

關於 ImmuCell Corp 公司

ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).

ImmuCell Corp簡介

公司代碼ICCC
公司名稱ImmuCell Corp
上市日期May 01, 1987
CEOte Boekhorst (Olivier)
員工數量69
證券類型Ordinary Share
年結日May 01
公司地址56 Evergreen Drive
城市PORTLAND
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編04103
電話12078782770
網址https://immucell.com/
公司代碼ICCC
上市日期May 01, 1987
CEOte Boekhorst (Olivier)

ImmuCell Corp公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Michael F. Brigham
Mr. Michael F. Brigham
Director
Director
216.70K
--
Dr. David Scott Tomsche, M.D.
Dr. David Scott Tomsche, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
131.39K
-1.55%
Ms. Bobbi Jo Brockmann
Ms. Bobbi Jo Brockmann
Vice President - Sales and Marketing, Director
Vice President - Sales and Marketing, Director
8.52K
--
Mr. Bryan K. Gathagan
Mr. Bryan K. Gathagan
Independent Director
Independent Director
1.00K
--
Mr. Paul R. Wainman
Mr. Paul R. Wainman
Independent Director
Independent Director
--
--
Mr. Steven T. Rosgen
Mr. Steven T. Rosgen
Independent Director
Independent Director
--
--
Ms. Gloria J. Basse
Ms. Gloria J. Basse
Independent Director
Independent Director
--
--
Mr. Timothy C. Fiori
Mr. Timothy C. Fiori
Chief Financial Officer, Treasurer, Secretary, Director
Chief Financial Officer, Treasurer, Secretary, Director
--
--
Mr. Olivier te Boekhorst
Mr. Olivier te Boekhorst
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Michael F. Brigham
Mr. Michael F. Brigham
Director
Director
216.70K
--
Dr. David Scott Tomsche, M.D.
Dr. David Scott Tomsche, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
131.39K
-1.55%
Ms. Bobbi Jo Brockmann
Ms. Bobbi Jo Brockmann
Vice President - Sales and Marketing, Director
Vice President - Sales and Marketing, Director
8.52K
--
Mr. Bryan K. Gathagan
Mr. Bryan K. Gathagan
Independent Director
Independent Director
1.00K
--
Mr. Paul R. Wainman
Mr. Paul R. Wainman
Independent Director
Independent Director
--
--
Mr. Steven T. Rosgen
Mr. Steven T. Rosgen
Independent Director
Independent Director
--
--

常見問題

ImmuCell Corp的前五大股東是誰?

ImmuCell Corp的前五大股東如下:Mr. Michael F. Brigham

有多少機構持有ImmuCell Corp(ICCC)的股份?

截至2026Q1,共有48家機構持有ImmuCell Corp的股份,合計持有的股份價值約為2.16M,占公司總股份的23.86% 。與2025Q4相比,機構持股有所增加,增幅為228934.00。

哪個業務部門對ImmuCell Corp的收入貢獻最大?

在2026Q1,First Defense® product line業務部門對ImmuCell Corp的收入貢獻最大,創收27.45M,占總收入的99.29% 。
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有